Actively Recruiting
Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)
Led by Centre Hospitalier Universitaire de la Guadeloupe · Updated on 2026-01-09
600
Participants Needed
3
Research Sites
104 weeks
Total Duration
On this page
Sponsors
C
Centre Hospitalier Universitaire de la Guadeloupe
Lead Sponsor
C
Centre Hospitalier Universitaire de la Réunion
Collaborating Sponsor
AI-Summary
What this Trial Is About
Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and linked to lipotoxicity. Analysis of PNPLA3 polymorphisms in an overseas territories population of MASLD would be interesting to describe their profile susceptibility to develop Metabolic dysfunction associated steatohepatitis (MASH).
CONDITIONS
Official Title
Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)
Who Can Participate
Eligibility Criteria
You may qualify if you...
IInclusion Criteria
-Adult patients (≥18 years old) seen in consultation or hospitalized in the Hepato-Gastroenterology Departments of the University Hospitals of Guadeloupe, French Guiana, and Réunion Island, with a diagnosis of MASLD.
MASLD is defined as evidence of hepatic steatosis associated with overweight/obesity, type 2 diabetes, or metabolic syndrome according to ATP III (2005) criteria.
- Patients affiliated with, or beneficiaries of, a social security scheme.
- Free, informed, and written consent obtained from the participant and signed by both the participant and the investigator (no later than the day of inclusion and prior to any procedure required by the study).
Exclusion Criteria:
- Patients under 18 years of age.
- Patients unable to provide informed consent; so-called vulnerable populations (individuals under guardianship, judicial protection, etc.).
- Presence of another cause of chronic liver disease, including:
Viral hepatitis (B, C, or E)
Primary biliary cholangitis or primary sclerosing cholangitis
Autoimmune hepatitis
Wilson's disease
Hemochromatosis
Alpha-1 antitrypsin deficiency
Alcoholic liver disease, or daily alcohol consumption >30 g/day for men or >20 g/day for women
-Pregnant women.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Centre Hospitalier Universitaire de la Guyane
Cayenne, French Guiana, 97306
Not Yet Recruiting
2
CHU de la Guadeloupe
Pointe-à-Pitre, Guadeloupe, 97159
Actively Recruiting
3
Centre Hospitalier Universitaire de la Réunion
Saint-Denis, Reunion, 97400
Not Yet Recruiting
Research Team
M
melanie petapermal
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here